Navigation Links
diaDexus Announces Name Change From VaxGen
Date:11/1/2010

SOUTH SAN FRANCISCO, Calif., Nov. 1, 2010 /PRNewswire-FirstCall/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced that the company, formerly known as VaxGen, Inc. and traded on the OTC Bulletin Board under the ticker symbol (VXGN), has been renamed diaDexus, Inc. diaDexus' common stock will continue to trade on the OTC Bulletin Board under a new ticker symbol, DDXS. The name change was approved by the diaDexus Board of Directors following a reverse merger transaction completed on July 28, 2010 between the former diaDexus, Inc., a privately held company, and VaxGen, Inc.

diaDexus plans to host a webcast after the filing of its Form 10-Q for the third quarter of 2010. An announcement of the time and date of the webcast and access details will be made about a week prior to the webcast. In the webcast, Patrick Plewman, the company's President & Chief Executive Officer, and David Foster, the company's Chief Financial Officer, will provide a corporate overview and discuss the company's third quarter 2010 financial results.

Patrick Plewman commented, "The merged company combines the cash resources of VaxGen with diaDexus' commercial diagnostics business and offers exciting growth prospects. We look forward to connecting with current shareholders and potential investors to share our vision and strategy."

The change in the company's name will not affect the validity or transferability of any existing stock certificates that bear the VaxGen, Inc. name. Stockholders may continue to hold these certificates. No action is required by stockholders at this time.

About diaDexus, Inc.

diaDexus, Inc., based in South San Francisco, California, is focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC ELISA Test for Lp-PLA2 is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States. For more information, please visit the company's website at www.diaDexus.com

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations and intentions with respect to future operations and products and other statements that are not historical in nature, particularly those that use terminology such as "will," "potential", "prospects," "could," "can," "believe," "intends," "continue," "plans," "expects," "estimates" or comparable terminology. Forward-looking statements are based on current expectations and assumptions, and entail various known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to diaDexus that could cause actual results to differ materially from those expressed in such forward-looking statements include risks related to general business and economic conditions; the failure to realize the anticipated benefits from the company's acquisition of the former diaDexus, Inc.;  the technical and commercial merits and potential of the company's diagnostic products; and the difficulty of developing pharmaceutical and diagnostic products, obtaining and maintaining regulatory and other approvals and achieving market acceptance. Additional factors that could cause diaDexus' results to differ materially from those described in the forward-looking statements can be found in diaDexus' most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and other reports filed with the Securities and Exchange Commission, and available at the SEC's web site at www.sec.gov. The information set forth herein speaks only as of the date hereof, and diaDexus disclaims any intention and does not assume any obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation ... on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, ... of therapeutic antibodies. , To meet this demand, the team at SCIEX ...
(Date:3/22/2017)... USA, and CARDIFF, UK (PRWEB) , ... March 21, 2017 , ... ... blood flow and tissue oxygenation, is being explored as a way to track the ... spectroscopy study on tonic pain activation by cold pressor test ,” published today in ...
(Date:3/22/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced Alexey ... present at the 5th Annual Cancer BioPartnering & ... to present to and meet with thought leaders ... companies as well as institutional investors. This event ...
(Date:3/20/2017)... ... March 20, 2017 , ... Avexegen Therapeutics Inc., an ... it has entered into an exclusive global license agreement with Children’s Hospital Los ... Enterocolitis (rare orphan disease) as well as Crohn’s Disease and Ulcerative Colitis. ...
Breaking Biology Technology:
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/22/2017)... , March 21, 2017 ... Cloud used by retailers such as 1-800-Flowers and ... platform — Product Recommendations and Replenishment. Using Optimove,s machine ... more personalized product and replenishment recommendations to their ... also on predictions of customer intent drawn from ...
(Date:3/22/2017)... Calif. , March 21, 2017 ... analytics company serving law enforcement agencies, announced today the ... as director of public safety business development. ... diversified law enforcement experience, including a focus on the ... In his most recent position, Mr. Sheridan served as ...
Breaking Biology News(10 mins):